- Gambogenic acid
-
- $0.00 / 1KG
-
2025-04-15
- CAS:173932-75-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500000kg
- Gambogenic acid
-
- $60.00/ kg
-
2025-04-15
- CAS:173932-75-7
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 5000kg/week
- Gambogenic acid
-
- $0.00 / 25KG
-
2025-03-21
- CAS:173932-75-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
|
| | Gambogenic acid Basic information |
| Product Name: | Gambogenic acid | | Synonyms: | Gambogenic acid;(2Z)-4-[(1R,3aS,5S,12aS)-9-[(2E)-3,7-Dimethyl-2,6-octadien-1-yl]-3a,4,5,7-tetrahydro-8,10-dihydroxy-3,3-dimethyl-11-(3-methyl-2-buten-1-yl)-7,13-dioxo-1,5-methano-1H,3H-furo[3,4-d]xanthen-1-yl]-2-methyl-2-butenoic acid;2-Butenoic acid, 4-[(1R,3aS,5S,12aS)-9-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]-3a,4,5,7-tetrahydro-8,10-dihydroxy-3,3-dimethyl-11-(3-methyl-2-buten-1-yl)-7,13-dioxo-1,5-methano-1H,3H-furo[3,4-d]xanthen-1-yl]-2-methyl-, (2Z)-;Gambogenic acid,Histone Methyltransferase,inhibit,Inhibitor;(Z)-4-((1R,3aS,5S,12aS)-9-((E)-3,7-Dimethylocta-2,6-dien-1-yl)-8,10-dihydroxy-2,2-dimethyl-11-(3-methylbut-2-en-1-yl)-4,7-dioxo-1,2,5,7-tetrahydro-1,5-methanofuro[2,3-d]xanthen-3a(4H)-yl)-2-methylbut-2-enoic acid;Gambogenic acid, 10 mM in DMSO | | CAS: | 173932-75-7 | | MF: | C38H46O8 | | MW: | 630.78 | | EINECS: | | | Product Categories: | | | Mol File: | 173932-75-7.mol |  |
| | Gambogenic acid Chemical Properties |
| Boiling point | 818.6±65.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 250 mg/mL (396.34 mM; Need ultrasonic) | | form | Powder | | pka | 4.58±0.36(Predicted) | | color | Light yellow to yellow |
| | Gambogenic acid Usage And Synthesis |
| Uses | Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer[1][2]. | | in vivo | Gambogenic acid (4-12 mg/kg, i.v., every 2 days, 14 days) inhibits tumor growth in SCLC mouse xenograft model[2].
| Animal Model: | SCLC mouse xenograft model[1] | | Dosage: | 4-12 mg/kg | | Administration: | i.v., every 2 days, 14 days | | Result: | Increased the expression of pro-apoptotic proteins (cleaved caspase-3, -8 and -9, Bax, cleaved PARP and p53 proteins).
Decreased the anti-apoptotic proteins (Bcl-2).
|
| | IC 50 | EZH2 | | References | [1] Wang X, et al. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J. 2017 May 2;36(9):1243-1260. DOI:10.15252/embj.201694058
[2] Huang T, et al. Gambogenic acid inhibits the proliferation of small?cell lung cancer cells by arresting the cell cycle and inducing apoptosis. Oncol Rep. 2019 Mar;41(3):1700-1706. DOI:10.3892/or.2018.6950 |
| | Gambogenic acid Preparation Products And Raw materials |
|